RU58841 is generally considered ineffective as a standalone hair loss treatment, with most users combining it with finasteride or dutasteride for better results. Few report success using RU58841 alone.
The user experienced significant hair improvement after one year using topical finasteride and minoxidil, combined with a hair transplant at the front. They switched from oral to topical finasteride due to side effects and are satisfied with the results, especially at the temples.
The user experienced hair regrowth and stopped hair loss using a natural DHT blocker and later finasteride, despite initial side effects. They plan to add topical minoxidil to address remaining thin spots.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
Nicotinamide serum is discussed for its potential benefits in reducing inflammation related to hair loss. One user combines it with minoxidil for hair growth.
A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.
User deciding between oral and topical minoxidil, concerned about hypertrichosis and myocarditis interaction. They're using topical finasteride, LLLT, natural oils, dermastamping, and scalp massage, and considering adding oral minoxidil.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
A user shared their successful hair regrowth journey using 1mg finasteride daily, 1ml minoxidil nightly, and weekly 1.5mm microneedling. They reported some side effects like reduced semen thickness but are satisfied with the results and recommend topical minoxidil over oral.
The user "AcanthocephalaNo7632" shared their progress with hair loss, mentioning the use of minoxidil and finasteride. Some users questioned the authenticity of the progress pictures.
A 30-year-old man shared his experience with finasteride, taking 1mg every other day, which led to sexual side effects and other issues, prompting him to stop the treatment despite initial hair improvement. He previously tried natural methods and minoxidil without much success and is now considering a buzzcut.
The conversation discusses the use of topical finasteride and minoxidil for hair loss and inquires about the effectiveness of adding RU58841. Participants share experiences and opinions on the potential benefits of including RU58841 in their treatment regimen.
The conversation is about a user trying a 0.2% Alfatrafiol treatment for hair loss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
The user has been using finasteride 1mg for a year and minoxidil 5% for 1.6 years, with inconsistent dermarolling, and is considering switching from topical to oral minoxidil due to hair dryness. They report increased hair thickness and no side effects, with plans to consult a dermatologist about the switch.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
The conversation is about whether 0.5 mg of finasteride reduces scalp DHT as effectively as 1 mg. Users suggest that even lower doses like 0.05 mg can significantly reduce scalp DHT.
The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.
The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.
A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.
The user regrets not using medication after a failed hair transplant and is now using a combination of minoxidil, finasteride, derma rolling, oils, and ketoconazole shampoo to try to improve hair regrowth. They are seeking feedback on progress and considering further treatment options.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.